ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2579

Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease

Richard Moore1, Lihong Huo1, Colin Koziel1, Barry Stripp2, Tiphanie Vogel3, Daniel Wallace4 and Caroline Jefferies5, 1Cedars-Sinai, Beverly Hills, CA, 2Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 3Baylor College of Medicine, Houston, TX, 4Cedars Sinai Medical Center, Studio City, CA, 5Cedars-Sinai Medical Center, Beverly Hills, CA

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, Innate Immunity Rheumatic Disease, interstitial lung disease, Mouse Models, Other, neutrophils

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Innate Immunity (2579–2584)

Session Type: Abstract Session

Session Time: 1:00PM-1:15PM

Background/Purpose: COPA syndrome is an autosomal dominant disease caused by missense mutations within the COPA gene. Typical onset begins during childhood with patients developing lung disease such as diffuse alveolar hemorrhage (DAH). Despite its severity, the cause of lung involvement in COPA syndrome is unknown. Here, we find that mutant COPA worsens and prolongs disease in a murine model of DAH and permits aberrant NETosis in humans and mice, offering a route by which lung disease may progress in patients with COPA syndrome.

Methods: Copa+/+ (WT), CopaR233H/+, and CopaR233H/R233H C57BL/6 mice were generated and treated with pristane to induce DAH. Tissues were isolated at 4, 14, or 21 days and analyzed by flow cytometry, ELISA, qPCR, immunofluorescence (IF), and H&E. Circulating whole blood, neutrophils, and plasma were isolated from healthy control (HC) and COPA patients and analyzed by IF, ELISA, and scRNA-seq. Primary lung basal epithelial cells (BECs) isolated from COPA lung explants and immortalized HC BECs were transfected with dsDNA and analyzed via qPCR.

Results: Unlike WT, mutant mice failed to recover from pristane-induced disease as observed by survival, development of DAH, and lung inflammation (Fig 1A-C). Mutant mice underwent dramatic granulopoiesis reflected in dominant neutrophil infiltrates within the BAL, lung, and peritoneum versus WT (Fig 2A). We found elevated neutrophil extracellular traps (NETs) within mutant BAL, and mutant neutrophils underwent increased NETosis compared to WT (Fig 2B-D). Additionally, scRNA-seq of human neutrophils revealed a highly elevated inflammatory signature in COPA versus HC, corroborated by increased NETosis and circulating NETs in these patients (Fig 3A-C). To ask how neutrophils may be recruited into the lung during COPA, we exposed human BECs to dsDNA to simulate alveolar NETs. COPA BECs generated a robust and prolonged inflammatory response compared to HC, specifically IFNB1 and the neutrophil chemoattractant CXCL10, suggesting an amplified capacity to recruit neutrophils (Fig 3D).

Conclusion: In summary, we found that COPAR233H exacerbates pristane-induced lung disease, is associated with increased NETosis, and permits excessive CXCL10 production in epithelial cells. Taken together, our data detail a route by which lung inflammation in COPA syndrome may be promoted in a feed-forward manner via aberrant NETosis and inflamed alveolar epithelium.

Supporting image 1Figure 1: Mice bearing the Copa-R233H allele develop worsened and protracted disease in response to pristane. A) Survival of mice in response to a single intraperitoneal dose of pristane. B) Presence of diffuse alveolar hemorrhage in lungs 2 weeks after pristane injection. C) H&E-stained left lung lobes from PBS- or pristane-treated mice 2 or 3 weeks after i njection (left) as quantified by relative stained area (right). Values are mean +/- SEM. Statistical significance was determined using Log-rank (Mantel-Cox) or Two-Way ANOVA tests. *p < 0.05, **p < 0.01.

Supporting image 2Figure 2: Copa-R233H promotes neutrophil infiltration into inflamed tissue and allows spontaneous and STING-dependent NETosis. A) Neutrophils as a percentage of CD11b+Ly6G+ of CD45+ cells within inflamed tissues 2 weeks after pristane injection. B) Presence of NETs, as measured by citH3::dsDNA complexes, within BAL fluid 2 weeks after pristane injection. C, D) Ability of peritoneal neutrophils to undergo NETosis in response to the STING agonist DMXAA or PMA, as measured by SYTOX+ via flow cytometry (C) and visualized via immunofluorescence (D, arrows). Values are mean +/- SEM. Statistical significance was determined using Two-Way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Supporting image 3Figure 3: COPA-R233H fails to restrain inflammation in patient neutrophils and epithelial cells. A) Neutrophils from patients with COPA syndrome display a dramatic inflammatory signature as determined via scRNA-seq. B, C) Patient neutrophils undergo spontaneous NETosis after 4 hours in culture (B), and patients have elevated circulating NETs as measured by MPO::dsDNA and NE::dsDNA complexes (C). D) COPA patient-derived basal epithelial cells fail to curb IFNB1 and CXCL10 transcript production in response to dsDNA transfection. Values are mean +/- SEM. Statistical significance was determined using Two-Way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.


Disclosures: R. Moore: None; L. Huo: None; C. Koziel: None; B. Stripp: None; T. Vogel: AstraZeneca, 5, moderna, 2, Pfizer, 2, SOBI, 1, 2, takeda, 6; D. Wallace: PPD, 2; C. Jefferies: None.

To cite this abstract in AMA style:

Moore R, Huo L, Koziel C, Stripp B, Vogel T, Wallace D, Jefferies C. Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/mutant-copa-permits-aberrant-netosis-and-exacerbates-autoimmune-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mutant-copa-permits-aberrant-netosis-and-exacerbates-autoimmune-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology